Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZEB antagonist
- Development stage
- Preclinical
- Lead developer
- Leuven Centre for Drug Design and Discovery
- Modality
- Small Molecules
01
Overview
ZEB antagonists are small molecule inhibitors developed by the Leuven Centre for Drug Design and Discovery (CD3) that target the Zinc finger E-box-binding homeobox (ZEB) family of transcription factors, specifically ZEB1 and ZEB2. These proteins are master regulators of the epithelial-mesenchymal transition (EMT), a cellular process that allows epithelial cancer cells to acquire mesenchymal properties, thereby increasing their motility, invasiveness, and resistance to apoptosis. By inhibiting ZEB activity, these compounds aim to reverse the EMT process, which can suppress metastatic spread, overcome resistance to chemotherapy and immunotherapy, and target cancer stem cell populations. The program is currently in the preclinical stage of development for the treatment of various solid cancers.
- Other names
- ZEB1/2 antagonistZEB inhibitorZEB1 antagonistZEB-1 antagonistZEB 1 antagonistZEB2 antagonistZEB-2 antagonistZEB 2 antagonist
02
Targets
ZEB1 (Zinc finger E-box-binding homeobox 1)ZEB2 (Zinc finger E-box-binding homeobox 2)
Beyond the preview
Go deeper on ZEB antagonist.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZEB antagonist.